Sagimet Biosciences (NASDAQ:SGMT) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Sagimet Biosciences (NASDAQ:SGMT) from a sell rating to a hold rating in a report issued on Saturday morning.

Several other research firms have also commented on SGMT. HC Wainwright reiterated a “buy” rating and issued a $29.00 price target on shares of Sagimet Biosciences in a research report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Sagimet Biosciences in a research report on Thursday, January 22nd. Citizens Jmp upped their target price on Sagimet Biosciences from $33.00 to $35.00 and gave the company a “market outperform” rating in a research note on Friday, November 14th. Citigroup reiterated an “outperform” rating on shares of Sagimet Biosciences in a report on Friday, November 14th. Finally, Barclays started coverage on Sagimet Biosciences in a research report on Tuesday, January 27th. They set an “equal weight” rating and a $8.00 price target for the company. Seven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $26.00.

Sagimet Biosciences Trading Down 2.4%

Shares of NASDAQ SGMT opened at $5.21 on Friday. The stock has a market cap of $169.44 million, a price-to-earnings ratio of -3.32 and a beta of 3.35. Sagimet Biosciences has a 52 week low of $1.73 and a 52 week high of $11.41. The company’s 50-day moving average price is $5.73 and its 200 day moving average price is $6.62.

Sagimet Biosciences (NASDAQ:SGMT) last posted its earnings results on Wednesday, March 11th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.14. As a group, research analysts expect that Sagimet Biosciences will post -1.6 earnings per share for the current year.

Insider Transactions at Sagimet Biosciences

In related news, CEO David Happel sold 12,101 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $5.36, for a total value of $64,861.36. Following the completion of the sale, the chief executive officer directly owned 677,621 shares in the company, valued at approximately $3,632,048.56. The trade was a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 14.70% of the company’s stock.

Hedge Funds Weigh In On Sagimet Biosciences

A number of hedge funds have recently made changes to their positions in the stock. Affinity Asset Advisors LLC grew its stake in shares of Sagimet Biosciences by 228.1% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,148,245 shares of the company’s stock valued at $6,798,000 after buying an additional 798,245 shares during the period. Millennium Management LLC increased its holdings in shares of Sagimet Biosciences by 6,484.7% during the 3rd quarter. Millennium Management LLC now owns 776,377 shares of the company’s stock worth $5,326,000 after buying an additional 788,537 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Sagimet Biosciences in the 4th quarter worth $4,620,000. Schonfeld Strategic Advisors LLC raised its position in shares of Sagimet Biosciences by 462.4% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 523,774 shares of the company’s stock worth $3,593,000 after buying an additional 430,644 shares during the period. Finally, Hudson Bay Capital Management LP acquired a new position in Sagimet Biosciences in the fourth quarter valued at $1,802,000. Institutional investors and hedge funds own 87.86% of the company’s stock.

Key Stories Impacting Sagimet Biosciences

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $29 price target, signaling continued bull case from the firm despite the cuts to some forecasts. HC Wainwright Research Note (summary)
• Positive Sentiment: Wall Street Zen published an upgrade on SGMT (reported by American Banking News), providing an additional positive signal from another market source. Sagimet Biosciences Upgraded at Wall Street Zen
• Neutral Sentiment: HC Wainwright slightly raised its FY2028 loss estimate (less negative: from ($3.30) to ($3.22)), a modest improvement but not a turnaround — suggests small model tweaks rather than material fundamental change. HC Wainwright FY2028 revision (summary)
• Negative Sentiment: HC Wainwright reduced several near- and mid‑term EPS forecasts: FY2027 worsened (from ($2.49) to ($2.62)), FY2029 was cut (from ($1.76) to ($1.87)), and quarterly FY2026 estimates were set as negative across Q1–Q4 (around ($0.50)–($0.54) per quarter). These downward revisions increase short‑term uncertainty and likely pressure the stock. HC Wainwright estimates and quarterly guidance (summary)

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.